TURNOVER (x1000 DKK)
NET PROFIT (x1000 DKK)
EMPLOYEES
Xvivo Perfusion AB
Closing information (x1000 DKK)
Closing information | 2022/12 (consolidated) | 2021/12 (consolidated) | 2020/12 (consolidated) |
Turnover | 277,512 | 187,881 | 133,306 |
Financial expenses | 37,216 | 14,692 | 9,248 |
Earnings before taxes | 14,911 | 4,846 | -42,441 |
EBITDA | 32,460 | -5,424 | |
Total assets | 1,158,104 | 1,121,670 | 852,564 |
Current assets | 312,404 | 398,128 | 343,328 |
Current liabilities | 90,142 | 75,999 | 53,547 |
Equity capital | 955,664 | 934,691 | 747,432 |
- share capital | 509 | 548 | 504 |
Employees (average) | 114 | 92 | 63 |
Financial ratios
Fiscal year | 2022/12 (consolidated) | 2021/12 (consolidated) | 2020/12 (consolidated) |
Solvency | 82.5% | 83.3% | 87.7% |
Turnover per employee | 2,434 | 2,042 | 2,116 |
Profit as a percentage of turnover | 5.4% | 2.6% | -31.8% |
Return on assets (ROA) | 4.5% | 1.7% | -3.9% |
Current ratio | 346.6% | 523.9% | 641.2% |
Return on equity (ROE) | 1.6% | 0.5% | -5.7% |
Change turnover | 104,850 | 57,098 | -30,370 |
Change turnover % | 61% | 44% | -19% |
Chg. No. of employees | 22 | 29 | 17 |
Chg. No. of employees % | 24% | 46% | 37% |
Total value of public sale
Fiscal year | 2022/12 (consolidated) | 2021/12 (consolidated) | 2020/12 (consolidated) |
Total value of public sale | 0 | 0 | 0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.